Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies

NCT04440943 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT04440943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04440943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Lead sponsor
Celldex Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
August 4, 2020
Completion date
April 6, 2023
Enrollment
27 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

bladder urothelial carcinoma, breast cancer, cholangiocarcinoma, esophageal cancer, fallopian tube cancer, gastric cancer, head and neck cancer, hepatic cancer, msi-h colorectal cancer, non-small cell lung cancer, other solid tumors, ovarian cancer, primary peritoneal carcinoma, renal cell carcinoma